Results of EssilorLuxottica’s mandatory public offer for GrandVision shares
Results of EssilorLuxottica’s mandatory public offer for GrandVision shares
• Acceptance Period ended 3 December 2021 (at 17:40 hours CET)
• 13.06% of the Shares have been tendered under the Offer during the Acceptance Period
• Including the 86.67% of the Shares already held by the Offeror, the Offeror will hold a total interest of 99.73%
• Settlement of the Offer will take place on 8 December 2021, at which date the Offer Price of Euro 28.42 per Share will be paid
• Remaining Shares can be tendered during the Post-Acceptance Period, commencing on 7 December 2021 at 09:00 hours CET and ending on 20 December 2021 at 17:40 hours CET
Charenton-le-Pont, France and Schiphol, the Netherlands (6 December, 2021 – 7:00am CET) – With reference to the press release of 7 October 2021 by EssilorLuxottica S.A. (the “Offeror“) and GrandVision N.V. (“GrandVision”) regarding the publication of the offer memorandum of the same date (the “Offer Memorandum”) for the recommended mandatory public offer (the “Offer”) by the Offeror to all holders of shares in GrandVision, the Offeror and GrandVision hereby announce the results of the Offer.
Terms not defined in this press release will have the meaning as set out in the Offer Memorandum.
During the Acceptance Period, which expired at 17:40 hours CET on 3 December 2021, 33,225,412 Shares have been tendered under the Offer, representing an interest of approximately 13.07% and an aggregate value of approximately Euro 944,266,209. Including the 220,537,421 Shares already held by the Offeror on the date hereof, the Offeror will hold a total of 253,762,833 Shares, representing approximately 99.73% of the issued share capital of GrandVision.
In accordance with Article 24 of the Decree, the closing (gestanddoening) of the Offer is not subject to conditions.
With reference to the Offer Memorandum, Shareholders who accepted the Offer shall receive the Offer Price for each Share validly tendered (or defectively tendered provided that such defect has been waived by the Offeror) and delivered (geleverd) on the terms and restrictions of the Offer.
Settlement of the Offer shall occur and payment of the Offer Price per Share validly tendered (or defectively tendered provided that such defect has been waived by the Offeror) shall take place on 8 December 2021.
The Offeror hereby announces that Shareholders who have not tendered their Shares during the Acceptance Period will have the opportunity to tender their Shares under the same terms applicable to the Offer, during the Post-Acceptance Period (na-aanmeldingstermijn) which will start on 7 December 2021, at 09:00 hours CET and end on 20 December 2021 at 17:40 hours CET.
The Offeror will publicly announce the results of the Post-Acceptance Period and the total amount and total percentage of Shares held by it in accordance with Section 17 paragraph 4 of the Decree no later than on the third Business Day following the last day of the Post-Acceptance Period.
The Offeror will continue to accept the transfer (levering) of all Tendered Shares during the Post-Acceptance Period and will pay the Offer Price for each Tendered Share that has been transferred (geleverd) to the Offeror promptly, but in any event within five Business Days following the date on which the relevant Shareholder transferred (geleverd) its Shares to the Offeror.
During the Post-Acceptance Period, Shareholders have no right to withdraw Tendered Shares from the Offer, regardless of whether the Shares have been tendered either during the Acceptance Period or the Post-Acceptance Period.
As a result of the Offeror holding more than 95% of the Shares, the Offeror and GrandVision intend to procure delisting of the Shares on Euronext Amsterdam as soon as possible under the applicable rules. Further details on the delisting will be announced when available. These steps are likely to have significant consequences for Shareholders who do not tender their Shares under the Offer. Reference is made to Section 5.11.2 (Liquidity, delisting of the Shares and post-closing steps) of the Offer Memorandum.
As the Offeror has acquired more than 95% of the Shares, the Offeror intends to initiate, as soon as possible, the Buy-Out. Reference is made to Section 5.11.4 (Buy-out proceedings) of the Offer Memorandum.
Further implications for non-tendering Shareholders
Remaining Shareholders who do not wish to tender their Shares in the Post-Acceptance Period should carefully review the sections of the Offer Memorandum that further explain the intentions of the Offeror, such as (but not limited to) Section 5.11 (Consequences of the Offer for non-tendering Shareholders), which describes certain implications to which such Shareholders may become subject with their continued shareholding in GrandVision.
Any announcement contemplated by the Offer Memorandum will be issued by press release.
Offer Memorandum, Position Statement and further information
This announcement contains selected, condensed information regarding the Offer and does not replace the Offer Memorandum and/or Position Statement. The information in this announcement is not complete and additional information is contained in the Offer Memorandum and Position Statement.
Digital copies of the Offer Memorandum are available on the website of the Offeror (www.essilorluxottica.com) and digital copies of the Offer Memorandum and Position Statement are available on the website of GrandVision (www.grandvision.com). Such websites do not constitute part of, and are not incorporated by reference into, the Offer Memorandum.
Copies of the Offer Memorandum and the Position Statement are also available free of charge from GrandVision and the Exchange Agent.
Evert van de Beekstraat 1-80
Tower C, 6th floor
ABN AMRO Bank N.V.
Corporate Broking and Issuer Services HQ7212
Gustav Mahlerlaan 10
1082 PP Amsterdam
Citigroup Global Markets Europe AG is acting as the Offeror’s financial adviser. Stibbe N.V. is acting as legal adviser to the Offeror as to Dutch law. Sullivan & Cromwell LLP is acting as the Offeror’s legal adviser for matters of U.S. and French law.
ING Bank N.V. is acting as GrandVision’s financial adviser. De Brauw Blackstone Westbroek N.V. is acting as GrandVision’s legal adviser.
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada26.1.2022 07:00:00 CET | Press release
Idorsia expands its commercialization partnership with Syneos Health for daridorexant in Europe and Canada Idorsia to capitalize upon the unique opportunity to transform the insomnia treatment paradigm, notably in Europe where daridorexant would be the first dual orexin receptor antagonist made available to patients with insomniaCollaboration with Syneos Health to effectively reach the primary care market in Europe and Canada Allschwil, Switzerland& Morrisville, N.C. – January26, 2022 Idorsia Ltd (SIX: IDIA), a leading Swiss biopharmaceutical company, and Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced the extension of an existing collaboration to commercialize daridorexant, a novel dual orexin receptor antagonist for the treatment of insomnia across Europe and Canada. Simon Jose, Chief Commercial Officer of Idorsia, commented: “Daridorexant represents a significant advance in the treatment of insomnia, and it is now our
Sharing of Staking Rewards Announcement26.1.2022 07:00:00 CET | Press release
January 26th 2022 CoinShares Digital Securities Limited CoinShares Physical Staked Tezos CoinShares Physical Staked Polkadot Sharing of Staking Rewards CoinShares Digital Securities Limited (the “Issuer”) hereby announces in accordance with Condition 5.3.2 of the Conditions of the CoinShares Digital Securities that Staking Rewards in relation to the class (the “Specified Class”) specified below will be applied by a reduction in the Management Fee applicable to the Specified Class to zero and a positive daily accrual to the Coin Entitlement to the Specified Class provided in the table below . Such reduction to the Management Fee and positive daily accrual to the Coin Entitlement shall apply from the start of trading on January 26th, 2022 until a date to be specified in a further announcement in accordance with Condition 5.3.2. ClassISINManagement FeeStaking Reward (positive daily accrual to Coin Entitlement) CoinShares Physical Staked Tezos GB00BMWB4803 Reduced to 0.0% p.a. 3.00% p.a. C
Aino Health AB (publ): Norberg & Partner Sustainable Group AB (publ) tecknar aktier i Aino Health AB (publ).25.1.2022 19:45:00 CET | Pressemelding
Detta pressmeddelande utgör inte ett offentligt uppköpserbjudande eller annars ett erbjudande om att förvärva aktier. Norberg & Partner Sustainable Group AB (publ)tecknar aktier i Aino Health AB (publ) och utlöser därmed budplikt. Norberg & Partner Sustainable Group AB (publ), org.nr 559268-0663 (”Norberg & Partner”) har idag tecknat 15 384 616 aktier i Aino Health AB (publ), org.nr 559063-5073 (”Aino Health”) till ett pris om 0,65 kronor per aktie. Efter förvärvet äger Norberg & Partner cirka 36,38 procent av aktierna och rösterna i Aino Health. Genom förvärvet utlöses budplikt, vilket innebär att Norberg & Partner är skyldig att offentliggöra ett budpliktsbud avseende resterande aktier i Aino Health inom fyra veckor från förvärvet, alternativt avyttra så många aktier så att aktieinnehavet representerar mindre än tre tiondelar av röstetalet för samtliga aktier i Aino Health. För ytterligare information, se Norberg & Partners hemsida. www.norbergpartner.se/ Kontaktperson: Jyrki Eklund,
Sword Group: 2021 Fourth Quarterly Results | Exceptional Profitability25.1.2022 19:15:00 CET | Press release
2021 Fourth Quarterly Results Consolidated Revenue: €59.7m Consolidated Growth: +31.8% Organic Growth: +21.9% EBITDA Margin: 15.0% RESULTS 4TH QUARTER 2021 Q4 (1) €m 2021 2020 Revenue 59.7 45.3 EBITDA 9.0 7.6 EBITDA Margin 15.0% 13.0% (1) non audited figures Organic growth on a like-for-like basis and at constant exchange rates: +21.9%. YEAR 2021 Consolidated Revenue: €214.6m Organic Growth: +21.5% EBITDA Margin: 13.6% ANALYSIS The Revenue for the Fourth Quarter of 2021 amounts to €59.7m in consolidated terms and to €55.2m without taking into account the acquisition of AiM, added to the perimeter on 1 July 2021. The EBITDA margin for the quarter amounts to 15.0% and organic growth to +21.9%. For 2021, the consolidated revenue amounts to €214.6m with an EBITDA margin of 13.6%. Organic growth for the year amounts to +21.5%. The Group established its 2021 Business Plan based on an organic growth hypothesis of 13%. Sword outperformed in terms of growth while maintaining and even exceeding
Aino Health AB (publ): The board of Aino Health resolves on a directed issue of shares to Norberg & Partner Sustainable Group AB (publ).25.1.2022 19:00:00 CET | Press release
This document in English is a translation of the original in Swedish. In case of any discrepancy, the Swedish original will prevail. The board of Aino Health AB (publ), reg. number 559063-5073 (the “Company”) has today, based on the authorisationfrom the annual general meeting on 24th of May 2021, resolved on a directed issue of 15 384 616 shares with deviation from the shareholders’ pre-emption right.The issue is directed to Norberg & Partner Sustainable Group AB (publ) (”Norberg & Partner”) in order to secure the Company’s long-term financing in a time-and cost-efficient manner and entails an estimated capital injection of approximately SEK 10 million. The subscription price was, after negotiations with the subscriber, determined to SEK 0.65 per new share, which corresponds to the market value as assessed by the board. The reason for the deviation from the shareholders’ pre-emptive right is to secure the Company’s long-term financing in a time- and cost-efficient manner. The new shar
Aino Health AB (publ): Styrelsen i Aino Health AB (publ) beslutar om en riktad nyemission till Norberg & Partner Sustainable Group AB (publ).25.1.2022 19:00:00 CET | Pressemelding
Styrelsen i Aino Health AB (publ), org.nr 559063-5073 (”Bolaget”) har, med stöd av bemyndigandet från årsstämman den 24 maj 2021, idag beslutat att genomföra en riktad nyemission av 15 384616 aktier med avvikelse från aktieägarnas företrädesrätt. Nyemissionen är riktad till Norberg & Partner Sustainable Group AB (publ) (”Norberg & Partner”) i syfte att säkra Bolagets långsiktiga finansiering och medför ett förväntat kapitaltillskott om ca 10 miljoner kronor. Teckningskursen har efter förhandling med teckningsberättigade fastställts till 0,65 kronor per aktie, vilket motsvarar av styrelsen bedömt marknadsvärde. Skälet till avvikelsen från aktieägarnas företrädesrätt är att emissionslikviden ska användas i syfte att på ett snabbt och kostnadseffektivt sätt stärka Bolagets långsiktiga finansiering. Betalning för de nyemitterade aktierna sker genom kontant betalning. Antalet aktier i Bolaget ökar med 15 384 616 aktier, från 26 901 155 aktier till 42 285 771 aktier. Aktiekapitalet i Bolaget
EXTRAORDINARY GENERAL MEETING APPROVES INCREASE OF CONDITIONAL CAPITAL AND SIKA PROPOSES ELECTION OF GORDANA LANDEN TO THE BOARD OF DIRECTORS25.1.2022 18:00:00 CET | Press release
EXTRAORDINARY GENERAL MEETING APPROVES INCREASE OF CONDITIONAL CAPITAL AND SIKA PROPOSES ELECTION OF GORDANA LANDEN TO THE BOARD OF DIRECTORS At an Extraordinary General Meeting, Sika’s shareholders approved the increase of conditional capital. Sika recommends the election of Gordana Landento the Board of Directors at the next Annual General Meeting, to be held on April 12, 2022. On January 25, 2022, an Extraordinary General Meeting of Sika AG was held. Based on Ordinance 3 of the Federal Council on measures to prevent the spread of COVID-19, it was not possible for shareholders to physically attend the Extraordinary General Meeting. Instead, shareholders cast their votes through the independent proxy. The shareholders approved an increase to the existing conditional capital from CHF 155,893.20 (corresponding to 15,589,320 registered shares with a par value of CHF 0.01 each) to CHF 187,893.20 (corresponding to 18,789,320 registered shares with a par value of CHF 0.01 each). Shareholder